Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of approximately 18,500 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. We support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.
In Advanced Synthesis, we apply more than 125 years’ expertise in classic and complex chemistry to the manufacturing of small molecules, highly potent APIs, antibody-drug conjugates and bioconjugates. Our comprehensive DPI development services utilizes micronization/jet milling and spray drying, with expertise in both small and large molecules, to engineer precise particle formulations for optimized respiratory drug delivery.
www.lonza.com
advanced.synthesis@lonza.com
Navigating the Development of Dry Powder for Inhalation: A CDMO Perspective
Interest in pulmonary/nasal drug delivery has grown due to solubility challenges, systemic side effects, and biologics. Newcomers need a CDMO-centric roadmap. This publication, authored by Lonza colleagues, provides a stepwise strategy covering target profiles, formulation choices, particle engineering (jet milling/spray drying), and encapsulation, offering a unified framework for inhaled drug development. More Info
Beyond Jet Milling: A Deep Dive into Carrier-Based Formulation and Process Optimization
This webinar explores the requirements for pulmonary drug delivery using carrier-based inhaled powder formulations. It covers jet milling techniques for producing stable, effective materials and their integration into formulation development. You will gain insights into dose flexibility, optimal drug delivery technologies, and risk assessment methods for selecting flexible dosing strategies. More Info
Dry Powder Inhalable Vaccines for Shelf Stability and Global Access
Watch this webinar to learn about dry powder formulation and manufacturing for inhaled vaccines, featuring a tuberculosis vaccine candidate from AAHI and Lonza. It covers spray drying for intranasal delivery, critical quality attributes, and aerosol performance, along with the global need for shelf-stable, non-invasive vaccines. More Info
De-Risking Early Phase Micronization with Integrated Solid Form Selection
Discover how to optimize solid form selection for successful jet milling in respiratory drug delivery. This session covers identifying suitable salts and cocrystals, evaluating micronization performance, and making informed preclinical decisions. A real-world case study will showcase key strategies for achieving the right particle size and maximizing yield. More Info
The Role of Excipients in Inhaled Biologics
The field of inhaled biologics is expanding, with dry and liquid formulations of proteins, peptides, and nucleic acids gaining momentum. This paper examines the role of excipients in ensuring stability, safety, and efficacy, addressing regulatory complexities, and providing insights into formulation considerations and the challenges in developing respiratory excipients. More Info
Formulation of Dry Powder Inhaler
Discover how spray drying, a leading particle engineering technique, is revolutionizing pharmaceutical manufacturing, particularly for inhaler formulations. This e-book highlights its advantages in particle control, stability, and potential for complex combination therapies. It also includes expert articles and webinars on improving pulmonary delivery and transforming patient care for rare diseases. More Info
